Acetogenic Bacteria Patents: Who Leads, Where the Gaps Are 2026
- Concentrated at the top. The five most active filers together hold 70.2% of all 104 records in scope, and the top ten hold 91.3% — this is a field with a small set of repeat filers, not a broad crowd.
- Filing activity has cooled from its 2022 peak. Filings peaked in 2022 at 24, and the tracked three-year span from 2021 to 2024 shows a 25% decline — though 2025 onward is still filling in as publications lag filing by roughly 18 months.
- Fermentation claims dominate the class mix. C12P (fermentation and enzymatic synthesis) appears in 95.2% of records and C12N (microorganisms and genetic engineering) in 99.0%, leaving peptide, bioinformatics and wastewater-adjacent classes as a thin minority.
Filing growth compares 2021 (4 records) with 2024 (3) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 104 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Acetogenic bacteria pathway balancing sits at the intersection of gas fermentation and metabolic engineering: strains that fix CO2 or CO into acetate, ethanol or higher-value carboxylic acids, tuned by enzyme ratio, precursor supply and byproduct suppression claims. The scope here pulls 104 published records filed against IPC classes covering microorganism cultivation, fermentation synthesis and enzyme/DNA-based measurement, filtered to documents that explicitly address flux, bottleneck or byproduct-control language rather than gas fermentation broadly.
The dataset spans filings from 2015 through the 2026-07-31 cut-off, with the earliest tracked year at 2017. Because publication trails filing by roughly a year and a half, the last one to two years understate true filing volume and should be read as provisional rather than a sign of decline.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 104-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend
Filings rose from 2 in 2017 to a peak of 24 in 2022, then eased — the tracked 2021-to-2024 window shows 4 down to 3, a 25% decline. Treat the final one to two years as incomplete rather than as evidence the field is winding down.
IPC composition
C12N and C12P together cover almost every record (99.0% and 95.2% of the 104 records respectively), confirming this is fundamentally a fermentation-and-organism-engineering field. Peptide claims (C07K, 15.4%), microorganism indexing (C12R, 10.6%) and the smaller categories — sugars/nucleic acids, enzyme/DNA measurement, bioinformatics and wastewater treatment — sit well behind, each under 3% of records and marking narrower, less-contested territory.
Shares are the percentage of the 104 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Acetogenic Bacteria Pathway Balancing with Eureka
This page is one run against one query. Ask Eureka your own question about acetogenic bacteria pathway balancing and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a recent filing
WO2026080418A1 — Systems, methods, processes, and microorganisms for the production of lipids from carbonaceous feedstock and industrial effluents
The filing describes a sequential bioprocess: a first anaerobic culture converts CO2 and hydrogen into carbonaceous feedstock, which then feeds a second aerobic culture engineered via adapted laboratory evolution and genetic engineering for high-yield lipid production. It combines strain development with bioprocess engineering across two linked bioreactor stages.Filed by Cemvita Factory, Inc. — dated 2026-04-16.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20040152159A1 | Materials and methods for the efficient production of acetate and other products | 152 |
| 2 | US20090148914A1 | Materials and methods for the efficient production of acetate and other products | 43 |
| 3 | US20170298363A1 | Non-natural microbial organisms with improved energetic efficiency | 15 |
| 4 | WO2021084526A1 | Engineered autotrophic bacteria for co2 conversion to organic materials | 9 |
| 5 | WO2023287814A2 | Carboxylic acid platform for fuel and chemical production at high carbon and energy efficiency | 8 |
| 6 | US20170159083A1 | Arginine supplementation to improve efficiency in gas fermenting acetogens | 8 |
| 7 | WO2021165229A1 | Method for the incorporation of formaldehyde into biomass | 7 |
| 8 | WO2004044210A2 | Materials and methods for the efficient production of acetate and other products | 6 |
| 9 | WO2021116330A1 | Novel genetically engineered microorganism capable of growing on formate, methanol, methane or co 2 | 4 |
| 10 | US10808262B2 | Microorganisms and methods for improving product yields on methanol using acetyl-CoA synthesis | 3 |
Citation counts favor older, longer-indexed records — read this as a signal of influence within the corpus, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern signals
Reading the concentration, timing and class data together points to a field with a small stable core of filers and thinner claim coverage away from core fermentation chemistry.
A small group holds most of the claim space
The top five filers together account for 70.2% of all 104 records in scope, rising to 91.3% across the top ten of the 29 ranked assignees. New entrants are filing into a field where the core fermentation and strain-engineering claims are already well staked out by a handful of repeat filers.
Activity peaked in 2022, then eased
Filings climbed from 2 in 2017 to a peak of 24 in 2022. The tracked 2021-to-2024 span shows a 25% decline, from 4 down to 3 — but with publication lagging filing by around 18 months, 2025 and 2026 figures are still incomplete and should not be read as a trend reversal yet.
Fermentation chemistry dwarfs peptide-level claims
C12N and C12P cover effectively the whole dataset, at 99.0% and 95.2% of the 104 records respectively. Peptide and protein claims under C07K sit at just 15.4%, and bioinformatics-tagged filings (G16B) appear in only 1.9% — suggesting protein-engineering and computational-design angles are comparatively open.
Joint filing is limited but not absent
Ten co-assignee pairs appear across the dataset, with the strongest pairing linked to eight shared records. Most filers, however, prosecute independently, which is consistent with a field still organised around individual corporate or university strain-engineering programs rather than broad consortia.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to acetogenic bacteria pathway balancing, with the prior art for and against each one.
Who is filing, and where the gate sits
The ranked assignee list covers 29 companies and institutions, counted in the 104 records in scope. A short group of firms holds most of the volume; recent-year momentum has flattened even among the historical leaders.
One filer leads by a wide margin
The top-ranked assignee holds 25 of the 104 records in scope, well ahead of fifth place at 8 and tenth place at 3. That gap between first and fifth defines the shape of the whole field: one dominant filer, a mid-tier of steady contributors, then a long tail.
A mid-tier cluster with modest but real volume
Between fifth and tenth place, record counts fall from 8 to 3 — enough to represent an active research program, not enough to challenge the leader's position. This tier is where university and government research bodies sit alongside smaller commercial filers.
Latest-year momentum has flattened across leaders
Several of the historically most active assignees show zero filings in the latest tracked year, including year-over-year drops as steep as -100% for one leader. Given the roughly 18-month publication lag, this likely reflects incomplete recent-year data rather than an actual halt in R&D.
| Assignee | Recent year | YoY |
|---|---|---|
| Genomatica, Inc. | 0 | -100% |
| LanzaTech, Inc. | 0 | — |
| LanzaTech NZ, Inc. | 0 | — |
| Max Planck Gesellschaft zur Foerderung der Wissenschaften e.V. | 0 | — |
| The University of Queensland | 0 | — |
| Technical University of Denmark | 0 | — |
| Yeda Research and Development Co. Ltd. | 0 | — |
| University of Florida Research Foundation, Inc. | 0 | — |
Where to take this
The dataset points to a concentrated core and several thinner branches. The next steps depend on whether you're clearing a product or scouting where to file.
Run a freedom-to-operate check on core fermentation claims
With C12N and C12P claims covering nearly the entire dataset and the top ten filers holding 91.3% of all 104 records, any strain-engineering or fermentation-tuning approach should be checked against the leading assignees' portfolios before development proceeds.
Check claim overlap in EurekaScout the under-claimed branches before they fill in
Peptide-level engineering, computational flux design and enzyme/DNA-based flux assays each sit under 16% of records. These are the areas most likely to still have open claim space for a first-mover filing.
Explore white space in EurekaTrack the 2025-2026 filings as they publish
Recent-year momentum reads as flat only because publication lags filing by about 18 months. Revisit the trend once 2025 filings finish publishing to see whether the 2022 peak was a one-off or part of a longer cycle.
Set a filing alert in EurekaCommon questions on this landscape
The assignee ranking covers 29 companies and institutions across 104 records in scope. The leading assignee holds 25 records, well ahead of the fifth-ranked filer at 8 and the tenth at 3 — a steep drop-off that shows this is a concentrated field rather than a broad one. The top five filers combined hold 70.2% of all records, and the top ten hold 91.3%, so most of the remaining 19 ranked assignees each contribute only one or a few filings.
Filing activity rose from 2 records in 2017 to a peak of 24 in 2022, then declined to 3 by 2024 — a 25% drop over that tracked three-year window. However, publication typically lags actual filing by roughly 18 months, so 2025 and 2026 figures in any dataset are still incomplete at the point of measurement. It is more accurate to say activity has cooled from its 2022 peak than to call the field currently in decline.
Almost all records fall under C12N (microorganisms and genetic engineering, 99.0% of the 104 records) and C12P (fermentation and enzymatic synthesis, 95.2%). Smaller but notable shares appear in C07K (peptides and proteins, 15.4%) and C12R (microorganism indexing, 10.6%), with sugars/nucleic acids, enzyme/DNA-based measurement, bioinformatics and wastewater treatment each under 3%. Because a single record can carry multiple IPC classes, these percentages add up to more than 100%.
The thinnest classes relative to the core fermentation claims are peptide-level engineering (C07K at 15.4%), bioinformatics-driven strain design (G16B at 1.9%) and enzyme/DNA-based flux measurement (C12Q at 2.9%). These sit well below the near-universal coverage of C12N and C12P, suggesting computational flux design and protein-level pathway tuning have comparatively less claim density. A first filer in these areas should still run a full freedom-to-operate check, since low volume does not guarantee the space is unclaimed by the leading assignees' broader portfolios.
The dataset records 10 co-assignee pairs, meaning most filers prosecute independently rather than jointly. The strongest pairing shares 8 records, well above the next strongest pairings at 2 to 3 shared records each. This pattern — limited but non-trivial joint filing concentrated among a couple of close partners — is typical of a field still organized around individual corporate or academic strain-engineering programs rather than industry-wide consortia.
Research Acetogenic Bacteria Pathway Balancing in depth with Eureka
Go past this page: query the whole acetogenic bacteria pathway balancing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.